MA55365A - Procédés de production de bioconjugués de polysaccharides o-antigènes d' e. coli, compositions de ceux-ci et leurs procédés d'utilisation - Google Patents

Procédés de production de bioconjugués de polysaccharides o-antigènes d' e. coli, compositions de ceux-ci et leurs procédés d'utilisation

Info

Publication number
MA55365A
MA55365A MA055365A MA55365A MA55365A MA 55365 A MA55365 A MA 55365A MA 055365 A MA055365 A MA 055365A MA 55365 A MA55365 A MA 55365A MA 55365 A MA55365 A MA 55365A
Authority
MA
Morocco
Prior art keywords
methods
compositions
producing
coli polysaccharide
antigen bioconjugates
Prior art date
Application number
MA055365A
Other languages
English (en)
Other versions
MA55365B1 (fr
Inventor
Darren Robert Abbanat
Martin Edward Braun
Pieter Jan Burghout
Sandmeier Maria Paula Carranza
Kellen Cristhina Fae
Fonck Veronica Gambillara
Jeroen Geurtsen
Yon Patricia Ibarra
Stefan Jochen Kemmler
Michael Thomas Kowarik
Manuela Mally
Jan Theunis Poolman
Eveline Marleen Weerdenburg
Original Assignee
Glaxosmithkline Biologicals Sa
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Janssen Pharmaceuticals Inc filed Critical Glaxosmithkline Biologicals Sa
Publication of MA55365A publication Critical patent/MA55365A/fr
Publication of MA55365B1 publication Critical patent/MA55365B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99018—Dolichyl-diphosphooligosaccharide—protein glycotransferase (2.4.99.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA55365A 2019-03-18 2020-03-18 Procedes de production de bioconjugues de polysaccharides o-antigenes d'e. coli, leurs compositions et leurs procedes d'utilisation MA55365B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962819762P 2019-03-18 2019-03-18
PCT/US2020/023415 WO2020191088A1 (fr) 2019-03-18 2020-03-18 Procédés de production de bioconjugués de polysaccharides o-antigènes d' e. coli, compositions de ceux-ci et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA55365A true MA55365A (fr) 2022-01-26
MA55365B1 MA55365B1 (fr) 2023-09-27

Family

ID=70285928

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55365A MA55365B1 (fr) 2019-03-18 2020-03-18 Procedes de production de bioconjugues de polysaccharides o-antigenes d'e. coli, leurs compositions et leurs procedes d'utilisation

Country Status (22)

Country Link
US (2) US11491220B2 (fr)
EP (2) EP4253554A3 (fr)
JP (1) JP2022525773A (fr)
KR (1) KR102574882B1 (fr)
CN (1) CN113950524A (fr)
AR (1) AR118389A1 (fr)
AU (1) AU2020240075A1 (fr)
BR (1) BR112021018258A2 (fr)
CA (1) CA3134045A1 (fr)
EA (1) EA202192392A1 (fr)
ES (1) ES2951442T3 (fr)
HR (1) HRP20231026T1 (fr)
HU (1) HUE063875T2 (fr)
IL (1) IL286467A (fr)
MA (1) MA55365B1 (fr)
MD (1) MD3942028T2 (fr)
MX (1) MX2021011418A (fr)
PL (1) PL3942028T3 (fr)
RS (1) RS64521B1 (fr)
SG (1) SG11202110303XA (fr)
TW (1) TWI771663B (fr)
WO (1) WO2020191088A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2711512C2 (ru) 2013-01-17 2020-01-17 Экс4 Фамасьютиклз (Остриэ) ГмбХ Рекомбинантное антитело, фармацевтический препарат, диагностический препарат, способ идентификации антитела-кандидата, способ лечения, профилактики и способ диагностики субъектов, потенциально подверженных риску заражения или страдающих от инфекций, вызванных штаммами Е. coli с множественной лекарственной устойчивостью
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
WO2020191082A1 (fr) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers
MX2023003169A (es) * 2020-09-17 2023-03-27 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas.
IL301880A (en) 2020-11-30 2023-06-01 Janssen Pharmaceuticals Inc Analytical method for glycoconjugation using a capillary-based immunoassay system
JP2024513914A (ja) 2021-04-08 2024-03-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド バイオコンジュゲート生産のためのプロセス

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
CA2284586C (fr) 1997-04-01 2011-02-08 Ribi Immunochem Research, Inc. Compositions d'adjuvant immunologique aqueuses de monophosphoryle lipide a
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
AU5162201A (en) 2000-04-13 2001-10-30 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
DE60303591T2 (de) 2002-03-07 2007-03-01 Eidgenössische Technische Hochschule Zürich System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
CN1324134C (zh) * 2003-12-22 2007-07-04 南开大学 对大肠杆菌o81型的o－抗原特异的核苷酸
ATE483027T1 (de) 2005-05-11 2010-10-15 Eth Zuerich Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP2242505A4 (fr) 2008-01-08 2012-03-07 Biogenerix Ag Glycoconjugaison de polypeptides employant des oligosaccharyltransférases
JP5782258B2 (ja) 2008-02-20 2015-09-24 グリコヴァキシン アーゲー 原核細胞由来の組換えｎ−グリコシル化タンパク質から作製したバイオコンジュゲート
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
CN102724997B (zh) 2009-11-19 2016-09-21 格林考瓦因有限公司 在原核细胞中产生免疫原性多糖的生物合成系统
CN103391714A (zh) 2010-12-10 2013-11-13 默沙东公司 减轻搅动引起的免疫原性组合物聚集的新制剂
JP2014526449A (ja) 2011-09-06 2014-10-06 グリコヴァキシン アーゲー 原核細胞において製造されるバイオコンジュゲートワクチン
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
BR112015004817A2 (pt) 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
EP2917351B1 (fr) * 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production d'un vaccin recombinant dans e. coli par conjugaison enzymatique
JP2016501550A (ja) 2012-12-27 2016-01-21 グリコヴァキシン アーゲー Ｃｒｍ１９７に関する方法及び組成物
RU2711512C2 (ru) 2013-01-17 2020-01-17 Экс4 Фамасьютиклз (Остриэ) ГмбХ Рекомбинантное антитело, фармацевтический препарат, диагностический препарат, способ идентификации антитела-кандидата, способ лечения, профилактики и способ диагностики субъектов, потенциально подверженных риску заражения или страдающих от инфекций, вызванных штаммами Е. coli с множественной лекарственной устойчивостью
LT2996473T (lt) 2013-05-18 2019-12-10 Aduro Biotech Inc Kompozicijos ir būdai, skirti aktyvuoti nuo "interferono geno stimuliatoriaus" priklausomą signalinį kelią
CA2926523C (fr) 2013-10-11 2023-09-26 Glycovaxyn Ag Methodes de modification de cellule hote
EP2870974A1 (fr) * 2013-11-08 2015-05-13 Novartis AG Vaccins conjugués de salmonelle
JP2016540764A (ja) 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
CA2935532A1 (fr) 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh Sequences d'anticorps specifiques diriges contre e. coli
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
ES2805000T3 (es) 2014-04-17 2021-02-10 Glaxosmithkline Biologicals Sa Células huéspedes modificadas y usos de las mismas
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
EP3240895B1 (fr) 2014-12-30 2022-01-26 GlaxoSmithKline Biologicals S.A. Compositions et methodes pour la glycosylation de proteine
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
WO2020191082A1 (fr) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef
MX2023003169A (es) 2020-09-17 2023-03-27 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas.

Also Published As

Publication number Publication date
AU2020240075A1 (en) 2021-10-14
US11491220B2 (en) 2022-11-08
CN113950524A (zh) 2022-01-18
HRP20231026T1 (hr) 2023-12-08
MA55365B1 (fr) 2023-09-27
BR112021018258A2 (pt) 2022-02-08
JP2022525773A (ja) 2022-05-19
EP3942028C0 (fr) 2023-06-07
PL3942028T3 (pl) 2023-10-23
KR102574882B1 (ko) 2023-09-04
EP3942028B1 (fr) 2023-06-07
EP4253554A3 (fr) 2024-01-17
MD3942028T2 (ro) 2023-11-30
TWI771663B (zh) 2022-07-21
WO2020191088A9 (fr) 2021-03-18
EP3942028A1 (fr) 2022-01-26
EP4253554A2 (fr) 2023-10-04
MX2021011418A (es) 2021-10-13
US20230190926A1 (en) 2023-06-22
US20200353073A1 (en) 2020-11-12
HUE063875T2 (hu) 2024-02-28
WO2020191088A1 (fr) 2020-09-24
AU2020240075A8 (en) 2021-10-21
KR20210134044A (ko) 2021-11-08
TW202102670A (zh) 2021-01-16
RS64521B1 (sr) 2023-09-29
CA3134045A1 (fr) 2020-09-24
SG11202110303XA (en) 2021-10-28
ES2951442T3 (es) 2023-10-20
IL286467A (en) 2021-12-01
EA202192392A1 (ru) 2022-02-09
EP3942028B9 (fr) 2023-08-23
AR118389A1 (es) 2021-09-29

Similar Documents

Publication Publication Date Title
MA55365A (fr) Procédés de production de bioconjugués de polysaccharides o-antigènes d' e. coli, compositions de ceux-ci et leurs procédés d'utilisation
IL286394A (en) Biological conjugates of polysaccharides e. coli o - antigen, methods for their production and methods for using them
MX2017005784A (es) Dextranos gelificantes enzimaticamente polimerizados.
CR20200140A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2019006868A (es) Derivados de polisacáridos anfifílicos y composiciones que los comprenden.
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
MX2021000229A (es) Composiciones oligosacaridicas y metodos para la produccion de estas.
EA201101164A1 (ru) Иммуногенная композиция
MY186349A (en) Oral care compositions and methods of use
EP4286000A3 (fr) Polysaccharides capsulaires de streptococcus pneumoniae et leurs conjugués
PH12019501199A1 (en) Calcium lactate compositions and methods of use
WO2016060996A3 (fr) Compositions d'interleukine-15 et leurs utilisations
WO2019053661A3 (fr) Dérivés de galnac
MX2021001716A (es) Composiciones novedosas, su uso y metodos para su formacion.
SG11202011573QA (en) Activated pectin-containing biomass compositions, products, and methods of producing
MX2019005855A (es) Formulaciones que se pueden pulverizar.
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos
SG11201907938RA (en) Pentosan Polysulfate, Pharmaceutical Composition, And Anticoagulant
MX2019000549A (es) Caramelo con una textura suave.
MX2020012800A (es) Cannabinoides y usos de los mismos.
WO2016198170A8 (fr) Vaccins contre le sérotype 5 de streptococcus pneumoniae
PH12016502386B1 (en) Oral care compositions
BR102016028651A2 (pt) polissacarídeos modificados.
BR112017028395A2 (pt) ?polissacarídeo capsular bacteriano, conjugado, e, composição farmacêutica?